Dr. Jacqueline Lui, President of Eagle IP Group, chaired a panel discussion titled “Intellectual Property Protection In Life Science” at the Hong Kong Biotech Horizon 2017: Global Congress on Biotechnology: Diagnostics and Therapeutics.
我们的过去活动
Recommended Insights
AI is magical but NOT magic! Be specific in your AI patents!
2025年1月9日What is the standard of sufficient disclosure for AI-related patents: A case study in China The rapid growth of AI patent applications present significant challenges to existing patent application and examination practices. One of them is satisfying the requirement for sufficient disclosure. The following case was featured in the 2023 CNIPA Compilation of Key Decisions […]
阅读更多 >
Beijing IP Court Reverses CNIPA Decision and Upholds Ozempic® semaglutide patent in China as VALID based on Novo Nordisk’s Post Filing Data
2024年6月27日Recently, all eyes have been on China as the fundamental patent covering semaglutide, the active ingredient in Ozempic® and Wegovy®, will expire on March 20, 2026. It goes without saying that generics are ramping up bigtime in China (and also around the world), preparing to manufacture and sell this blockbuster drug to one of the […]
阅读更多 >
China Releases Draft Examination Guidelines for the new Patent Law
2020年12月4日The Chinese Patent Office (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but not limited […]
阅读更多 >
2019 CHINA TOP 10 IP CASE: VALEO V. LUCAS, FUKE, & CHEN
2020年6月8日Every year in the spring The Supreme People’s Court of PRC announces its “Top 10 Intellectual Property (IP) cases” and “50 typical IP cases in Chinese courts” of the year. Although not having precedential weight, these cases serve as a reference and guide people's courts at all levels regarding their intellectual property trials. It’s always […]
阅读更多 >